Physician profile
Gerald A Frank
NPI 1912043787
$9,743.12
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,012 · 2020: $1,312 · 2021: $2,630 · 2022: $1,956 · 2023: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.38 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,786.54 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,426.21 | 2019-2023 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,142.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $999.06 | 2019-2023 | |
| Lilly USA, LLC | $732.50 | 2019-2023 | Mounjaro |
| Esperion Therapeutics, INC. | $493.26 | 2021-2022 | |
| Abbvie INC. | $457.38 | 2021-2023 | |
| Amarin Pharma, INC. | $443.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $426.48 | 2019-2022 | |
| Pfizer INC. | $304.27 | 2019-2021 | |
| Amgen INC. | $298.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $214.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $172.50 | 2019-2023 | |
| Mdd US Operations, LLC | $159.90 | 2019 | |
| Boston Scientific Corporation | $115.08 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $110.69 | 2021-2022 | |
| Abbott Laboratories | $109.76 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $65.27 | 2019-2020 | |
| Biogen, INC. | $52.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $42.63 | 2021-2023 | Crysvita |
| Allergan, INC. | $35.75 | 2019-2020 | |
| Dexcom, INC. | $35.56 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.85 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $18.84 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.78 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $18.73 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.32 | 2021 | |
| Horizon Therapeutics Plc | $16.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.